Jun

15

2022

What are FDA-approved indications for recombinant factor VIIa?

By William Aird

  • Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
  • Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia.

Related FAQs: